Evidence map›Paper›PMID 41988367›Full record

ArticleACS pharmacology & translational science2026

Development of Cathepsin B‑Activatable Cell-Penetrating Peptides for Tumor Targeting.

Konstantin Kuhne, Lydia Strohbach, Christin Neuber, Robert Wodtke, Gloria Ruiz-Gómez, Birgit Belter, Florian Brandt, Lara Gluhacevic von Krüchten, Max Keller, M Teresa Pisabarro and 3 more

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Konstantin KuhneInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.
Lydia StrohbachInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.
Christin NeuberInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.
Robert WodtkeInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.ORCID https://orcid.org/0000-0001-7462-7111
Gloria Ruiz-GómezBIOTEC, Technische Universität Dresden, Tatzberg 47-49, Dresden 01307, Germany.
Birgit BelterInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.
Florian BrandtInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.
Lara Gluhacevic von KrüchtenInstitute of Pharmacy, Faculty of Chemistry and Pharmacy, Universität Regensburg, Universitätsstraße 31, Regensburg 93053, Germany.
Max KellerInstitute of Pharmacy, Faculty of Chemistry and Pharmacy, Universität Regensburg, Universitätsstraße 31, Regensburg 93053, Germany.ORCID https://orcid.org/0000-0002-8095-8627
M Teresa PisabarroBIOTEC, Technische Universität Dresden, Tatzberg 47-49, Dresden 01307, Germany.ORCID https://orcid.org/0000-0002-5175-9311
Klaus KopkaInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.
Jens PietzschInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.ORCID https://orcid.org/0000-0002-1610-1493
Reik LöserInstitute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden 01328, Germany.ORCID https://orcid.org/0000-0003-1531-7601

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular cathepsin B is a driver of tumor progression and metastasis, and its potential as a diagnostic and prognostic marker is increasingly recognized. To harness its activity for triggering the uptake of activatable cell-penetrating peptides (ACPPs)

Indexed as

kinetic hysteresisPET imagingpharmacokineticsprotease substratesradiometal-based labelingtheranostics

Identifiers

PMID41988367
PMCPMC13077498

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.